Skip to content
Read our coverage of Compass Pathways' Phase 3 results.
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
Menu
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
Menu
  • Pα+
Search
Join Pα+
  • Sign in
Menu
  • Sign in
Join Pα+
Search
Close this search box.
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Menu
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Join Pα+
Search
Close this search box.
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Menu
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in

Psychedelics Company Profiles

Click on a company name below to view key financials, press releases and interviews.

Atai Life Sciences Logo White

ATAI Life Sciences

Beckley Psytech Company Profile

Beckley Psytech

Better Plant Sciences Company Profile

Better Plant Sciences (PLNT)

CaaMTech Company Profile

CaaMTech

Champignon Brands Company Profile

Champignon Brands Inc. (SHRM)

Compass Pathways Company Profile

COMPASS Pathways (CMPS)

Cybin Company Profile

Cybin Inc.

Eleusis Company Profile

Eleusis

Entheon Biomedical

Field Trip FTRP Company Profile

Field Trip (FTRP)

Havn Life Company Profile

Havn Life (HAVN)

Hollister Biosciences Company Profile

Hollister Biosciences (HOLL)

MagicMed Company Profile

MagicMed Industries

MindMed MMED Company Profile

MindMed (MMED)

Mydecine Innovations Company Profile

Mydecine Innovations Group (MYCO)

Numinus Company Profile

Numinus (NUMI)

Revive Therapeutics Company Profile

Revive Therapeutics Ltd. (RVV)

AI-powered Search

Your Pα+ account

Sign in

Quick Links

  • InsightsOpens in a new tab
  • JobsOpens in a new tab
  • DataOpens in a new tab
  • Subscribe to Pα+Opens in a new tab
  • ContactOpens in a new tab
  • Webcast Notes Compass
    Compass Provides Fuller Phase 3 Picture, MADRS Curves, on WebcastFebruary 17, 2026
  • Header - Breaking- Second Positive Phase 3 for Compass’ Psilocybin, Though Modest Magnitude Invites Debate
    BREAKING: Second Positive Phase 3 for Compass’ Psilocybin, Though Modest Magnitude Raises QuestionsFebruary 17, 2026
  • Q4'25 Psychedelic Lobbying Update
    Q4’25 Psychedelic Lobbying UpdateFebruary 13, 2026
  • Michael Cola Helus QA
    Taking the Helm at Helus: A Brief Q&A With New CEO Michael ColaFebruary 10, 2026
  • The Psychedelic Practitioner Issue 3 Dosing
    The Psychedelic Practitioner Issue 3: DosingFebruary 10, 2026

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond. Psy Alpha Ltd is a company registered in England and Wales (16989109).

Quick Links

  • Insights
  • Jobs
  • Data
  • Subscribe to Pα+
  • Contact

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.

Subscribe to Pα+
  • Psychedelic Alpha © 2026, All Rights Reserved
  • Privacy Policy
  • Terms of Service

Subscribe to Our Free Newsletter

Join Pα+ for Premium Insights

Subscribe Annually ($200)
Subscribe Monthly ($20)
Learn More